Concepts (173)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lung Neoplasms | 11 | 2019 | 247 | 1.100 |
Why?
|
| Biomarkers, Tumor | 4 | 2014 | 101 | 0.380 |
Why?
|
| Thoracotomy | 2 | 2010 | 9 | 0.380 |
Why?
|
| Thoracic Surgery, Video-Assisted | 2 | 2009 | 7 | 0.350 |
Why?
|
| Pneumonectomy | 2 | 2009 | 34 | 0.340 |
Why?
|
| Adenocarcinoma | 5 | 2015 | 61 | 0.330 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 4 | 2014 | 106 | 0.310 |
Why?
|
| Barrett Esophagus | 3 | 2015 | 10 | 0.310 |
Why?
|
| Catheter Ablation | 3 | 2015 | 21 | 0.310 |
Why?
|
| Intraoperative Complications | 1 | 2009 | 29 | 0.290 |
Why?
|
| Aged | 13 | 2019 | 4000 | 0.240 |
Why?
|
| Positron-Emission Tomography | 1 | 2006 | 36 | 0.230 |
Why?
|
| Female | 16 | 2019 | 6974 | 0.220 |
Why?
|
| Male | 15 | 2019 | 6815 | 0.220 |
Why?
|
| Pleurodesis | 1 | 2003 | 1 | 0.190 |
Why?
|
| Pleural Effusion, Malignant | 1 | 2003 | 3 | 0.190 |
Why?
|
| Drainage | 1 | 2003 | 26 | 0.190 |
Why?
|
| Echinocandins | 2 | 2012 | 4 | 0.180 |
Why?
|
| Neoplasm Staging | 6 | 2019 | 168 | 0.170 |
Why?
|
| Humans | 17 | 2019 | 12240 | 0.170 |
Why?
|
| Prognosis | 4 | 2014 | 363 | 0.160 |
Why?
|
| Treatment Outcome | 7 | 2015 | 1478 | 0.150 |
Why?
|
| Retrospective Studies | 5 | 2014 | 1467 | 0.150 |
Why?
|
| Middle Aged | 10 | 2015 | 4043 | 0.150 |
Why?
|
| Small Cell Lung Carcinoma | 1 | 2019 | 6 | 0.150 |
Why?
|
| Aged, 80 and over | 7 | 2014 | 2152 | 0.150 |
Why?
|
| False Positive Reactions | 1 | 2019 | 23 | 0.150 |
Why?
|
| Unnecessary Procedures | 1 | 2019 | 16 | 0.140 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2019 | 70 | 0.140 |
Why?
|
| Sensitivity and Specificity | 2 | 2009 | 252 | 0.130 |
Why?
|
| Mutagenicity Tests | 1 | 2016 | 1 | 0.120 |
Why?
|
| Teratogens | 1 | 2016 | 1 | 0.120 |
Why?
|
| Fetal Development | 1 | 2016 | 2 | 0.120 |
Why?
|
| Hazardous Substances | 1 | 2016 | 2 | 0.120 |
Why?
|
| Models, Animal | 1 | 2016 | 74 | 0.120 |
Why?
|
| Registries | 3 | 2015 | 88 | 0.120 |
Why?
|
| Cytokines | 2 | 2014 | 107 | 0.120 |
Why?
|
| Length of Stay | 2 | 2009 | 126 | 0.120 |
Why?
|
| Toxicity Tests | 2 | 2012 | 4 | 0.110 |
Why?
|
| Esophagoscopy | 1 | 2015 | 8 | 0.110 |
Why?
|
| Learning Curve | 1 | 2015 | 7 | 0.110 |
Why?
|
| Thoracoscopy | 2 | 2019 | 12 | 0.110 |
Why?
|
| Esophageal Neoplasms | 1 | 2015 | 22 | 0.110 |
Why?
|
| Insulin-Like Growth Factor Binding Proteins | 1 | 2014 | 5 | 0.110 |
Why?
|
| Neovascularization, Pathologic | 1 | 2014 | 15 | 0.110 |
Why?
|
| Insulin-Like Growth Factor II | 1 | 2014 | 9 | 0.110 |
Why?
|
| Clinical Competence | 1 | 2015 | 96 | 0.100 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2014 | 36 | 0.100 |
Why?
|
| Interleukin-2 Receptor alpha Subunit | 1 | 2013 | 7 | 0.100 |
Why?
|
| Solitary Pulmonary Nodule | 1 | 2013 | 7 | 0.090 |
Why?
|
| Multiple Pulmonary Nodules | 1 | 2013 | 9 | 0.090 |
Why?
|
| Fundoplication | 1 | 2012 | 12 | 0.090 |
Why?
|
| Radiosurgery | 2 | 2010 | 17 | 0.090 |
Why?
|
| Gastroesophageal Reflux | 1 | 2012 | 17 | 0.090 |
Why?
|
| Immunoassay | 1 | 2012 | 18 | 0.090 |
Why?
|
| Algorithms | 3 | 2014 | 169 | 0.090 |
Why?
|
| Embryonic Development | 1 | 2012 | 3 | 0.090 |
Why?
|
| Nitriles | 1 | 2012 | 5 | 0.090 |
Why?
|
| Embryo, Mammalian | 1 | 2012 | 12 | 0.090 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2012 | 69 | 0.090 |
Why?
|
| Pyrimidines | 1 | 2012 | 16 | 0.090 |
Why?
|
| Risk Assessment | 2 | 2012 | 295 | 0.090 |
Why?
|
| Triazoles | 1 | 2012 | 14 | 0.090 |
Why?
|
| Antifungal Agents | 1 | 2012 | 15 | 0.090 |
Why?
|
| Pyrazoles | 1 | 2012 | 35 | 0.090 |
Why?
|
| Fistula | 1 | 2011 | 2 | 0.090 |
Why?
|
| Gastric Fistula | 1 | 2011 | 3 | 0.090 |
Why?
|
| Esophagectomy | 1 | 2011 | 14 | 0.090 |
Why?
|
| Hospitals, Community | 1 | 2011 | 7 | 0.080 |
Why?
|
| Heart Diseases | 1 | 2011 | 31 | 0.080 |
Why?
|
| Community-Institutional Relations | 1 | 2011 | 6 | 0.080 |
Why?
|
| Medical Oncology | 1 | 2011 | 23 | 0.080 |
Why?
|
| Minority Groups | 1 | 2011 | 40 | 0.080 |
Why?
|
| Clinical Trials as Topic | 1 | 2011 | 100 | 0.080 |
Why?
|
| Prospective Studies | 4 | 2015 | 817 | 0.080 |
Why?
|
| Patient Selection | 1 | 2011 | 111 | 0.080 |
Why?
|
| Neoplasms | 1 | 2011 | 94 | 0.080 |
Why?
|
| Multivariate Analysis | 3 | 2015 | 141 | 0.080 |
Why?
|
| Survival Rate | 2 | 2010 | 152 | 0.080 |
Why?
|
| Probability | 1 | 2009 | 45 | 0.070 |
Why?
|
| Statistics, Nonparametric | 1 | 2009 | 72 | 0.070 |
Why?
|
| Thoracic Surgery | 1 | 2009 | 13 | 0.070 |
Why?
|
| Survival Analysis | 1 | 2009 | 99 | 0.070 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2009 | 85 | 0.070 |
Why?
|
| Area Under Curve | 3 | 2014 | 39 | 0.070 |
Why?
|
| Recurrence | 2 | 2014 | 126 | 0.070 |
Why?
|
| Predictive Value of Tests | 3 | 2014 | 218 | 0.070 |
Why?
|
| Rats | 3 | 2016 | 407 | 0.070 |
Why?
|
| Laparoscopy | 1 | 2009 | 95 | 0.070 |
Why?
|
| Age Factors | 1 | 2009 | 350 | 0.070 |
Why?
|
| Animals | 4 | 2016 | 2092 | 0.070 |
Why?
|
| Minimally Invasive Surgical Procedures | 1 | 2009 | 142 | 0.070 |
Why?
|
| Tumor Burden | 1 | 2007 | 14 | 0.060 |
Why?
|
| Lung | 2 | 2005 | 76 | 0.060 |
Why?
|
| Cohort Studies | 1 | 2009 | 827 | 0.060 |
Why?
|
| Risk Factors | 3 | 2015 | 1049 | 0.060 |
Why?
|
| United States | 3 | 2015 | 989 | 0.060 |
Why?
|
| Adult | 4 | 2014 | 3557 | 0.060 |
Why?
|
| Pneumonia | 2 | 2019 | 33 | 0.060 |
Why?
|
| Protein-Lysine 6-Oxidase | 1 | 2005 | 2 | 0.060 |
Why?
|
| Carcinoma, Bronchogenic | 1 | 2005 | 4 | 0.060 |
Why?
|
| ROC Curve | 2 | 2014 | 78 | 0.050 |
Why?
|
| Catheters, Indwelling | 1 | 2003 | 9 | 0.050 |
Why?
|
| Proton Pump Inhibitors | 2 | 2012 | 9 | 0.040 |
Why?
|
| Rats, Inbred F344 | 2 | 2012 | 22 | 0.040 |
Why?
|
| Time Factors | 2 | 2015 | 695 | 0.040 |
Why?
|
| Reoperation | 2 | 2015 | 366 | 0.040 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2014 | 281 | 0.040 |
Why?
|
| Follow-Up Studies | 2 | 2014 | 726 | 0.040 |
Why?
|
| Postoperative Complications | 2 | 2015 | 385 | 0.040 |
Why?
|
| Young Adult | 2 | 2014 | 863 | 0.040 |
Why?
|
| Radiography | 2 | 2013 | 258 | 0.040 |
Why?
|
| Mediastinoscopy | 1 | 2019 | 5 | 0.040 |
Why?
|
| Bronchoscopy | 1 | 2019 | 14 | 0.040 |
Why?
|
| Early Detection of Cancer | 1 | 2019 | 59 | 0.040 |
Why?
|
| Abnormalities, Drug-Induced | 1 | 2016 | 3 | 0.030 |
Why?
|
| Rabbits | 1 | 2016 | 110 | 0.030 |
Why?
|
| Least-Squares Analysis | 1 | 2015 | 5 | 0.030 |
Why?
|
| Hospitals, Low-Volume | 1 | 2015 | 3 | 0.030 |
Why?
|
| Hospitals, High-Volume | 1 | 2015 | 4 | 0.030 |
Why?
|
| Remission Induction | 1 | 2015 | 45 | 0.030 |
Why?
|
| Linear Models | 1 | 2015 | 115 | 0.030 |
Why?
|
| Logistic Models | 1 | 2015 | 196 | 0.030 |
Why?
|
| Minnesota | 1 | 2014 | 6 | 0.030 |
Why?
|
| Illinois | 1 | 2014 | 110 | 0.030 |
Why?
|
| Disease Progression | 1 | 2014 | 290 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2014 | 324 | 0.020 |
Why?
|
| Incidence | 1 | 2014 | 338 | 0.020 |
Why?
|
| Chemokine CCL3 | 1 | 2013 | 7 | 0.020 |
Why?
|
| Granuloma | 1 | 2013 | 11 | 0.020 |
Why?
|
| Chemokine CXCL12 | 1 | 2013 | 8 | 0.020 |
Why?
|
| Interleukin 1 Receptor Antagonist Protein | 1 | 2013 | 9 | 0.020 |
Why?
|
| Interleukin-10 | 1 | 2013 | 11 | 0.020 |
Why?
|
| Respiratory Tract Infections | 1 | 2013 | 12 | 0.020 |
Why?
|
| Interleukin-6 | 1 | 2013 | 48 | 0.020 |
Why?
|
| Decision Support Techniques | 1 | 2012 | 24 | 0.020 |
Why?
|
| Lymphatic Metastasis | 1 | 2012 | 51 | 0.020 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2013 | 95 | 0.020 |
Why?
|
| Maternal Exposure | 1 | 2012 | 1 | 0.020 |
Why?
|
| Voriconazole | 1 | 2012 | 7 | 0.020 |
Why?
|
| Injections, Subcutaneous | 1 | 2012 | 12 | 0.020 |
Why?
|
| Fetus | 1 | 2012 | 20 | 0.020 |
Why?
|
| Drug Combinations | 1 | 2012 | 17 | 0.020 |
Why?
|
| Tissue Distribution | 1 | 2012 | 18 | 0.020 |
Why?
|
| Cesarean Section | 1 | 2012 | 20 | 0.020 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2012 | 18 | 0.020 |
Why?
|
| Animals, Newborn | 1 | 2012 | 29 | 0.020 |
Why?
|
| Administration, Oral | 1 | 2012 | 55 | 0.020 |
Why?
|
| Feeding Behavior | 1 | 2012 | 40 | 0.020 |
Why?
|
| Body Weight | 1 | 2012 | 72 | 0.020 |
Why?
|
| Hematemesis | 1 | 2011 | 2 | 0.020 |
Why?
|
| Stomach Ulcer | 1 | 2011 | 2 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2012 | 179 | 0.020 |
Why?
|
| Esophageal Perforation | 1 | 2011 | 7 | 0.020 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2011 | 10 | 0.020 |
Why?
|
| Fatal Outcome | 1 | 2011 | 28 | 0.020 |
Why?
|
| Pregnancy | 1 | 2012 | 193 | 0.020 |
Why?
|
| Bone and Bones | 1 | 2012 | 83 | 0.020 |
Why?
|
| Osteogenesis | 1 | 2012 | 84 | 0.020 |
Why?
|
| Research Design | 1 | 2012 | 79 | 0.020 |
Why?
|
| Candidiasis | 1 | 2011 | 13 | 0.020 |
Why?
|
| Sex Factors | 1 | 2012 | 229 | 0.020 |
Why?
|
| Michigan | 1 | 2011 | 7 | 0.020 |
Why?
|
| Sex Distribution | 1 | 2011 | 34 | 0.020 |
Why?
|
| Hospitalization | 1 | 2012 | 158 | 0.020 |
Why?
|
| Program Evaluation | 1 | 2011 | 55 | 0.020 |
Why?
|
| Healthcare Disparities | 1 | 2011 | 34 | 0.020 |
Why?
|
| Mice | 1 | 2012 | 760 | 0.020 |
Why?
|
| Radiotherapy Dosage | 1 | 2007 | 42 | 0.020 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 1 | 2007 | 23 | 0.020 |
Why?
|
| Aging | 1 | 2012 | 680 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2005 | 68 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2005 | 157 | 0.010 |
Why?
|